bumetanide and Water-Electrolyte Imbalance studies

Water-Electrolyte Imbalance: Disturbances in the body's WATER-ELECTROLYTE BALANCE.

Research Excerpts

Excerpt	Relevance	Reference
"In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo."	9.51	Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022)
"In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo."	5.51	Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022)
"Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment."	2.87	Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. ( Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV, 2018)
"Forty patients with generalized cancer complicated by water and electrolyte retention were treated with "medium" and "large" doses of furosemide and bumetanide with 35% and 40% objective positive response, respectively."	1.26	Diuretics in malignant effusions and edemas of generalized cancer. ( Athanasiou, A; Dadiotis, L; Razis, DV, 1976)

Research

Studies (6)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Diastolic Blood Pressure

Change in Extracellular Water

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (50.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	1 (16.67)	2.80

Authors	Studies
Solis-Jimenez, F	1
Perez-Navarro, LM	1
Cabrera-Barron, R	1
Chida-Romero, JA	1
Martin-Alemañy, G	1
Dehesa-López, E	1
Madero, M	1
Valdez-Ortiz, R	1
Hallow, KM	1
Helmlinger, G	1
Greasley, PJ	1
McMurray, JJV	1
Boulton, DW	1
Mehta, RL	1
Cantarovich, F	1
Shaw, A	1
Hoste, E	1
Murray, P	1
Pellerito, R	1
Bertola, D	1
Soragna, A	1
Jayakumar, S	1
Puschett, JB	1
Razis, DV	1
Athanasiou, A	1
Dadiotis, L	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933]	Phase 2	34 participants (Actual)	Interventional	2019-06-18	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mmHg (Mean)
Placebo	-3.4
Treatment Grup	-13.5

Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Extracellular Water / Total Body Water Ratio

Intervention	litres (Mean)
Placebo	-0.15
Treatment Grup	2.55

Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Mean Arterial Pressure

Intervention	percentage of ECW/TBW (Mean)
Placebo	-0.24
Treatment Grup	-2.92

decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Systolic Blood Pressure

Change in the Fractional Excretion of Sodium

Intervention	mmHg (Mean)
Placebo	-5.4
Treatment Grup	-18.1

Intervention	mmHg (Mean)
Placebo	-10
Treatment Grup	-26.1

Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Total Body Water

Intervention	percentage of sodium excreted (Mean)
Placebo	-0.348
Treatment Grup	0.598

Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28

Article	Year
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. BMC nephrology, 2022, 09-20, Volume: 23, Issue:1 Topics: Aged; Bumetanide; Chlorthalidone; Humans; Hypertension; Middle Aged; Renal Insufficiency, Chronic; R	2022
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3 Topics: Adult; Benzhydryl Compounds; Blood Volume; Bumetanide; Diuresis; Diuretics; Drug Combinations; Drug	2018

Article	Year
Pharmacologic approaches for volume excess in acute kidney injury (AKI). The International journal of artificial organs, 2008, Volume: 31, Issue:2 Topics: Acute Kidney Injury; Ascites; Bumetanide; Diuretics; Fluid Therapy; Furosemide; Heart Failure; Hepat	2008
[Clinical use of bumetanide]. La Clinica terapeutica, 1981, Sep-30, Volume: 98, Issue:6 Topics: Blood Pressure; Bumetanide; Diuresis; Diuretics; Edema; Electrolytes; Female; Heart Failure; Humans;	1981
Study of the sites and mechanisms of action of bumetanide in man. The Journal of pharmacology and experimental therapeutics, 1977, Volume: 201, Issue:1 Topics: Administration, Oral; Bumetanide; Diuresis; Diuretics; Electrolytes; Hemodynamics; Humans; Infusions	1977
Diuretics in malignant effusions and edemas of generalized cancer. Journal of medicine, 1976, Volume: 7, Issue:6 Topics: Ascites; Body Weight; Bumetanide; Diuretics; Drinking; Edema; Furosemide; Humans; Neoplasms; Pleuris	1976

bumetanide and Water-Electrolyte Imbalance